Streamlining Cancer Diagnostic Tests for Effective Immunotherapy at AstraZeneca
5 May 2016
Dr Marianne Ratcliffe of Personalised Healthcare and Biomarkers at AstraZeneca, discusses research that demonstrates the interchangeability of PD-L1 assays and how these diagnostics can be better used to select effective immunotherapies for cancer patients.
About the company
SelectScience
Established in July 1998, SelectScience is the fastest way to impartial, expert opinion about the best laboratory equipment and latest techniques.
